FIELD: immunology.
SUBSTANCE: use of a synergetic combination of CD19 antibody and ibrutinib is proposed. Besides, a method for the treatment is considered.
EFFECT: present invention can be further used in the therapy of non-Hodgkin lymphoma, chronic lymphocytic leukemia and acute lymphoblastic leukemia expressing CD19.
36 cl, 20 dwg, 18 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMBINATION OF CD19 ANTIBODY WITH BCL-2 INHIBITOR AND ITS APPLICATION METHODS | 2017 |
|
RU2756405C2 |
| TREATMENT APPROACH DESIGNED TO TREAT WITH A COMBINATION OF ANTI-CD19 ANTIBODY AND VENETOCLAX | 2018 |
|
RU2802812C2 |
| COMBINATIONS AND USE THEREOF | 2016 |
|
RU2767063C2 |
| PROTEIN BINDING WITH NKG2D, CD16 AND WITH TUMOR-SPECIFIC ANTIGEN | 2018 |
|
RU2826991C2 |
| FORMULATIONS BASED ON CD19 ANTIBODY | 2017 |
|
RU2748024C2 |
| TREATMENT OF MALIGNANT TUMOR USING ANTI-CD19 ANTIGEN CHIMERIC RECEPTOR | 2015 |
|
RU2815417C2 |
| TYPES OF COMBINATION THERAPY USING CHIMERIC ANTIGEN RECEPTORS AND PD-1 INHIBITORS | 2017 |
|
RU2809160C2 |
| METHODS AND COMPOSITIONS FOR ADMINISTRATION OF DOSES OF ALLOGENEIC T-CELLS WITH CHIMERIC ANTIGEN RECEPTOR | 2018 |
|
RU2776322C2 |
| ANTI-CD79B ANTIBODY, ANTIGEN-BINDING FRAGMENT THEREOF AND PHARMACEUTICAL USE THEREOF | 2020 |
|
RU2817143C2 |
| CELL | 2015 |
|
RU2768019C2 |
